Tricyclic coumarin sulphonate derivatives with alkaline phosphatase inhibitory effects: <i>in vitro</i> and docking studies

<p>Tissue-nonspecific alkaline phosphatase (TNAP) is an important isozyme of alkaline phosphatases, which plays different pivotal roles within the human body. Most importantly, it is responsible for maintaining the balanced ratio of phosphate and inorganic pyrophosphate, thus regulates the extracellular matrix calcification during bone formation and growth. The elevated level of TNAP has been linked to vascular calcification and end-stage renal diseases. Consequently, there is a need to search for highly potent and selective inhibitors of alkaline phosphatases (APs) for treatment of disorders associated with the over-expression of APs. Herein, a series of tricyclic coumarin sulphonate <b>1a-za</b> with known antiproliferative activity, was evaluated for AP inhibition against human tissue nonspecific alkaline phosphatase (<i>h</i>-TNAP) and human intestinal alkaline phosphatase (<i>h-</i>IAP). The methylbenzenesulphonate derivative <b>1f</b> (IC₅₀ = 0.38 ± 0.01 μM) was found to be the most active <i>h</i>-TNAP inhibitor. Another 4-fluorobenzenesulphonate derivative <b>1i</b> (IC₅₀ = 0.45 ± 0.02 μM) was found as the strongest inhibitor of <i>h</i>-IAP. Some of the derivatives were also identified as highly selective inhibitors of APs. Detailed structure-activity relationship (SAR) was investigated to identify the functional groups responsible for the effective inhibition of AP isozymes. The study was also supported by the docking studies to rationalise the most possible binding site interactions of the identified inhibitors with the targeted enzymes.